NCT06350630 Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study Status NOT_YET_RECRUITING Phase PHASE2
NCT05942625 A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects Status RECRUITING Phase PHASE1
NCT05852938 A Study of Zigakibart in Adults With IgA Nephropathy Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT05834738 Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy Status COMPLETED Phase PHASE2
NCT05824390 A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy Status UNKNOWN Phase PHASE4
NCT05775042 Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy Status RECRUITING Phase PHASE2
NCT05687890 A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT05596708 Study of Telitacicept in Patients With Refractory IgA Nephropathy Status NOT_YET_RECRUITING Phase PHASE2/PHASE3
NCT05528991 Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy Status UNKNOWN Phase N/A
NCT05398510 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenously/Subcutaneously in Healthy Subject Status COMPLETED Phase PHASE1
NCT05190848 Correlation of Microbiome and Metabonomics With IgA Nephropathy Status RECRUITING Phase N/A
NCT05182775 A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy Status COMPLETED Phase NA
NCT05125068 Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) Status TERMINATED Phase PHASE2
NCT05083364 Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease Status COMPLETED Phase PHASE1/PHASE2
NCT05016323 A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. Status COMPLETED Phase PHASE2
NCT04905212 A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy Status TERMINATED Phase PHASE2